Navigating the New Diabetes Drugs Cardiovascular benefits and when to use
The recent introduction of antihyperglycaemic medications that not only improve glycated haemoglobin (HbA1c) levels but also provide cardiovascular, renal and overall mortality benefit renews hope for better management of diabetes. The new sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are potential game changers for people with T2D. Evidence shows that besides improving glyacaemic control, these drugs have renal, cardiovascular and all-cause mortality benefits.
Modern Medicine – Issue 5 2020
